(WWJ) Wayne State University is looking for volunteers for phase three of a clinical trial for a new COVID-19 vaccine candidate manufactured by Novavax.
At least 300 volunteers are needed; especially people age 65 and older, those with underlying medical conditions, and people of different racial and ethnic groups.
Two out of three participants will be randomly selected to receive injections of the vaccine, while the remaining one-third will receive a placebo. Participants will be followed for 24 months post-vaccination to monitor their health and safety.
The Phase 3 clinical trial will enroll up to 30,000 people at up to 115 sites in the U.S. and Mexico. The purpose is to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, building on research from Phase 1 and 2 studies.
"We are fortunate to be able to offer this opportunity in Detroit, which has been particularly struck hard by the pandemic,” said Elizabeth Secord, M.D., who will oversee the trial at Wayne State. “The initial phases of the trials have been promising. We hope to further test the vaccine candidate in segments of the population that have been identified as high risk to infection by COVID-19.”
Study volunteers will be seen initially at Wayne State University’s Integrative Biosciences Center, or IBio building, located at 6135 Woodward Ave. in Detroit.
Those interested should send an email to Dr. Secord, at firstname.lastname@example.org.